1/41
Vocabulary practice flashcards covering pathophysiology, assessment, diagnostic criteria, psychopharmacology, and clinical management across adult mental health conditions from the GNUR 650 lectures.
Adverse Childhood Experiences (ACEs)
Potentially traumatic events occurring during childhood (prior to age 10 on standard screening tools) linked to risky health behaviors, chronic disease, lower socioeconomic potential, and early death in adulthood.

The Pair of ACEs Framework
A visual framework developed by Ellis (2020) illustrating that individual Adverse Childhood Experiences (the tree branches, e.g., abuse, neglect, maternal depression) are rooted in and sustained by Adverse Community Environments (the tree roots, e.g., poverty, discrimination, community disruption, poor housing, and violence).
Recovery-Oriented Language
Non-stigmatizing, person-centered phrasing used in clinical documentation and patient care, such as substituting 'declined' for 'refused', 'chose not to' for 'resisted', 'seeking alternatives' for 'manipulative', 'not in agreement' for 'noncompliant', and 'person diagnosed with alcohol use disorder' for 'alcoholic'.
Monoamine Hypothesis of Depression
A pathophysiological theory positing that depressive symptoms stem from a functional depletion of the monoamine neurotransmitters serotonin, norepinephrine, and dopamine, which can be restored by pharmacologic agents blocking their reuptake transporters.
Mesolimbic Dopamine Pathway
The principal neurobiological reward and reinforcement circuit originating in the ventral tegmental area and projecting to the ventral striatum (nucleus accumbens); all substances capable of inducing dependence trigger explosive dopamine release within this circuit.
Major Depressive Disorder (MDD)
A mood disorder requiring a minimum of 2 weeks of persistent symptoms, featuring at least 5 out of 9 specific diagnostic criteria (with at least one being depressed mood or anhedonia) present on most days, resulting in significant clinical distress or functional impairment.
depression presentation
__ presentation
Sadness/tearfulness
Anhedonia
Change in weight or appetite
Insomnia or hypersomnia
Psychomotor agitation
Fatigue/energy loss
Feelings of worthlessness or guilt
Diminished concentration or indecisiveness
Suicidal ideation
depression treatment
__ treatmnet
1st line pharm = SSRIs
CBT
Social support
ECT
Light therapy
ssris
fluoxetine, sertraline, escitalopram, citalopram
ADRs:
insomnia/agitation
QTc prolongation
GI distress
Wt. gain
Sexual dysfunction
Drowsiness
Anticholinergic effects
serotonin syndrome
A potentially life-threatening condition resulting from excessive serotonergic activity in the nervous system, often caused by the use of certain medications or drug interactions.
Sx:
AMS
myoclonus
hyperreflexia
hallucinations
seizures
tachycardia/HTN
GI sx
1-2d
follow up interval when starting a acutely depressed pt on meds
red flags
Hallucinations
Delusions
Suicidal or homicidal thoughts
Extreme self-care deficit
Asverse effect after medications prescribed
sadpersonas
A mnemonic used to assess suicide risk that includes factors
Sex
Age
Depression
Previous attempt
Ethanol abuse
Rational thinking loss
Social support loss
Organized plan
No spouse
Availability of lethal means
Sickness
snris
duloxetine, velafaxine, desvenlafaxine
TCA
Amitriptyline, nortriptyline
maois
isocarboxazid, phenelzine, tranylcypromine, and selegiline
50 (%)
What percentage of symptom reduction is the goal with pharmacology for depression?
Dysthymia (Persistent Depressive Disorder)
A chronic depressive state marked by depressed mood most of the day, for more days than not, lasting at least 2 years in adults (1 year in children and adolescents) accompanied by at least 2 of 6 core symptoms, without being asymptomatic for more than 2 months at a time.
Generalized Anxiety Disorder (GAD)
Persistent, excessive, and uncontrollable worry occuring on more days than not for at least 6mo accompanied by sx like muscle tension, fatigue, restlessness, poor concentration, sleep impairment, and irritability.
anxiety differentials
__ differentials
Cancer
MV prolapse
Arrhythmia
CHF
Ischemic heard dx
Asthma/COPD
OSA
PE
Hypercapnia or hypoxia
Meniere’s dx
CVA/TIA
MS
Encephalopathy
SDH
Thyroid disorder
Cushing’s/Addison’s
Altered glucose levels
Folate/B12/iron deficiency
Rx (amniophylline, dig, lidocaine, NSAIDs, steroids)
OTC meds (ephedrine/pseudoephedrine, caffeine, salicylates)
Illicit drugs
anxiety treatment
__ treatment
SSRIs or SNRIs
Buspirone
Hydroxyzine for insomnia
Gabapentin
CBT
monthly
Initial follow up interval for GAD treatment
anxiety diagnostics
__ diagnostics
BMP
ECG
Thyroid function
rule out metabolic causes
Buspirone
A serotonin 1A (5-HT1A) receptor partial agonist approved as a non-benzodiazepine anxiolytic for the treatment of generalized anxiety disorder, having no potential for abuse or physical dependence.
Alpha-2-Delta (\alpha_2\delta) Ligands
Anticonvulsant compounds such as gabapentin and pregabalin that bind open voltage-sensitive calcium channels in the amygdala and corticostriatal-thalamocortical (CSTC) circuits, attenuating excitatory neurotransmitter release to reduce anxiety, fear, and worry.
Panic Disorder
An anxiety condition marked by recurrent, unexpected panic attacks alongside persistent anticipatory anxiety about future attacks or their consequences, commonly leading to maladaptive phobic avoidance behaviors.
Post-Traumatic Stress Disorder (PTSD)
A trauma- and stressor-related condition persisting for over 1 month following exposure to severe psychological trauma, characterized by intrusive memories/flashbacks, persistent avoidance of trauma cues, negative alterations in mood/cognition, and alterations in arousal and reactivity.
Clinician-Administered PTSD Scale (CAPS)
A 30-item structured clinical diagnostic interview considered the gold standard assessment tool for post-traumatic stress disorder, evaluating symptom onset, duration, distress, functional impairment, and interval change.
Prazosin
A centrally active alpha-1 adrenergic receptor antagonist frequently prescribed off-label in PTSD management to specifically alleviate trauma-related nightmares and nocturnal hyperarousal.
SBIRT
A comprehensive, evidence-based public health approach standing for Screening, Brief Intervention, and Referral to Treatment, designed to deliver early intervention for individuals with or at risk for substance use disorders.
CAGE Questionnaire
A 4-item screening questionnaire for identifying alcohol use disorder over the past 12 months, assessing whether the patient has felt the need to Cut down, felt Annoyed by criticism, felt Guilty, or used an Eye-opener drink in the morning.
Disulfiram
An aversive conditioning medication for chronic alcohol use disorder that irreversibly inhibits aldehyde dehydrogenase, causing an accumulation of acetaldehyde that produces nausea, vomiting, facial flushing, and hypotension if ethanol is ingested.
Acamprosate
A maintenance medication for alcohol dependence that modulates neurochemical balance by inhibiting excitatory glutamate neurotransmission and enhancing inhibitory gamma-aminobutyric acid (GABA) neurotransmission.
Naltrexone
A competitive μ-opioid receptor antagonist that attenuates the intoxicating reward properties of alcohol and opioids; available in oral formulation (Revia) and a long-acting monthly intramuscular injection (Vivitrol), requiring an opioid-free interval of at least 7 days before initiation.
Naloxone
A rapid-acting, synthetic opioid receptor antagonist administered parenterally or intranasally to quickly reverse life-threatening respiratory depression and coma induced by opioid overdose.
Buprenorphine
A high-affinity partial μ-opioid receptor agonist that prevents exogenous opioids from binding, effectively relieving opioid withdrawal symptoms and craving without producing substantial euphoria.
Clonidine
A centrally acting alpha-2 adrenergic agonist used in acute opioid detoxification to suppress autonomic hyperactivity symptoms (diarrhea, abdominal cramps, diaphoresis, tachycardia) without modifying subjective opioid cravings.
Chronic Insomnia Disorder
According to the ICSD-3-TR, a sleep disorder defined as difficulty initiating sleep, maintaining sleep, or waking earlier than desired (with latency/awakenings >30 minutes) occurring at least 3 times per week for at least 3 months, causing daytime impairment despite adequate sleep opportunity.
Spielman 3P Model of Insomnia
A behavioral model of chronic insomnia conceptualized by three components: Predisposing factors (baseline traits increasing vulnerability), Precipitating events (acute stressors that trigger sleep disruption), and Perpetuating factors (compensatory behaviors and cognitive habits sustaining poor sleep over time).
Dual Orexin Receptor Antagonists (DORAs)
A class of insomnia medications including daridorexant, lemborexant, and suvorexant that selectively block hypocretin/orexin receptors to suppress wakefulness signals, suitable for sleep-onset and sleep-maintenance insomnia.
Adult ADHD DSM-5 Diagnostic Threshold
The requirement that adults manifest at least 5 persistent symptoms in the inattention category, the hyperactivity/impulsivity category, or both for at least 6 months, with evidence that several symptoms were present before age 12 years across multiple settings.
Adult ADHD Self-Report Scale (ASRS-v1.1)
An 18-item standardized symptom checklist derived from DSM-IV/DSM-5 criteria used to screen for and assess the frequency of adult ADHD symptoms over the preceding 6 months.